Greater China Junior Stocks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Greater China Junior Stocks

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Julius Wong who wrote (792)	3/17/2005 1:27:40 AM
From: konasurfs1968	Read Replies (1) of 1992

For anyone interested in latest DRUG.OB numbers, the co. is updating website and has put this up which reflects the completed merger. Be aware of short term wekness in the stock price of DRUG.OB. Typical for reverse merger plays to sell off after merger is complete. New insiders may want to get some quick cash as they sell their newly acquired shares. CEO hold 31 million shares, or 50% of total o/s. In addition, their stock is listed on the Berlin-Bremen exchange where naked short sellers are abound and like to feast on bb stocks. Do your DD and decide if any s/t weakness is an opportunity. Kind Regards Share Outstanding (January 24, 2005): 65,109,004 2003 Full Year Pro-forma Financials Revenues of $29.7 million Net profit of $5.6 million (Net profit margin of 18.8%) Earning per share of $0.09 (based on 65.1 million shares) 2004 First Nine Months Pro-forma Financials: Revenues of $24.6 million Net profit of $6.4 million (Net profit margin of 26%) Earning per share of $0.10 (based on 65.1 million shares) No. of Employees: Approximately 2,500 Major Products: 35 pharmaceutical products (mainly anti-infectious drugs, including 13 prescription drugs and 22 Over-the-counter drugs) 2 chemical products (Clavulanic Acid and 7-ACA) 2 biotech products (EPO & G-CSF) Products Approval Obtained in China:293 product permits in 9 categories: 130 types of tablets 14 types of granules 10 types of suppositories 23 types of capsules 1 type of powder 54 types of powder for injections 15 types of bulk drugs 44 types of injection 2 types of biotech injectables (including in-licensed G-CSF) Chinese Sales Network: 63 sales offices covering all 31 provinces/regions with over 1,200 sales representatives International Sales Network: Licensees for EPO products covering over 130 countries Manufacturing Capabilities:Pharma division Powder for Injection with an annual capacity of 80 million vials Tablets with an annual capacity of 520 million units Capsules with an annual capacity of 90 million units Granules with an annual capacity of 47 million sachets Suppositories with an annual capacity of 10 million units Sterilized bulk drug with an annual capacity of 180 tonsChemical division Clavulanic Acid with an annual capacity of 30 tons 7-ACA with an annual capacity of 400 tons Biotech division EPO with an annual capacity of 72 grams bulk

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next